<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Conferences</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>As IVL technologies advance, Shockwave looks to defend its lead</title>
      <description>
        <![CDATA[As interests and competition in the intravascular lithotripsy (IVL) market heats up, Shockwave Medical Inc. said it believes that its latest coronary IVL catheter, the C2 Aero, and other projects in the pipeline, will help it to maintain its leadership in calcium modification.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731372</guid>
      <pubDate>Thu, 21 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731372-as-ivl-technologies-advance-shockwave-looks-to-defend-its-lead</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Shockwave-C2-Aero-IVL-5-21.webp?t=1779396208" type="image/jpeg" medium="image" fileSize="82703">
        <media:title type="plain">Shockwave Medical - C2 Aero coronary IVL</media:title>
        <media:description type="plain">C2 Aero coronary IVL catheter. Credit: Shockwave Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>RPT-E-037 shows promise as PDAC therapeutic</title>
      <description>
        <![CDATA[Pancreatic ductal adenocarcinoma (PDAC) is still a highly lethal cancer with limited therapeutic options. Its lethality mainly stems from activating KRAS mutations and a metabolic dependence on nicotinamide adenine dinucleotide (NAD). Researchers from Remedy Plan Inc. have presented data on RPT-E-037, which exerts dual targeting of NAD metabolism through Nampt inhibition and KRAS signaling inhibition using a pan-RAS inhibitor (RMC-6236).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731236</guid>
      <pubDate>Thu, 21 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731236-rpt-e-037-shows-promise-as-pdac-therapeutic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas.webp?t=1603307217" type="image/png" medium="image" fileSize="528517">
        <media:title type="plain">Pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Recludix presents STAT1/3 inhibitors for dermatological diseases</title>
      <description>
        <![CDATA[Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731235</guid>
      <pubDate>Thu, 21 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731235-recludix-presents-stat1-3-inhibitors-for-dermatological-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Dermatologic-atopic-dermatitis2.webp?t=1588881560" type="image/png" medium="image" fileSize="357317">
        <media:title type="plain">Skin irritation on hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Subgroup analysis of the Champion-AF trial shows age not a factor</title>
      <description>
        <![CDATA[A subgroup analysis of data from Boston Scientific Corp.’s Champion-AF trial, which looked at the outcomes for patients with atrial fibrillation treated with a left atrial appendage closure (LAAC) device compared to direct oral anticoagulants (DOACs), found that the efficacy and safety of LAAC compared to DOAC are not affected by age. The data were presented at the EuroPCR conference in Paris.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731344</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731344-subgroup-analysis-of-the-champion-af-trial-shows-age-not-a-factor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Boston-Scientific-Watchman-FLX-.webp?t=1779309137" type="image/jpeg" medium="image" fileSize="104199">
        <media:title type="plain">Boston Scientific Watchman FLX</media:title>
        <media:description type="plain">Watchman FLX left atrial appendage closure device. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>All Women data show Allegra edge in female TAVR patients</title>
      <description>
        <![CDATA[Data from the All Women clinical trial, which looked at the Allegra transcatheter aortic valve replacement (TAVR) system compared to balloon-expandable valves (BEV) in women with aortic stenosis, showed that Allegra delivered lower mean gradients and less prosthesis-patient mismatch than BEVs. The data presented at the EuroPCR conference in Paris was the first randomized head-to-head comparison of different TAVR platforms conducted exclusively in women.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731340</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731340-all-women-data-show-allegra-edge-in-female-tavr-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Biosensors-International-Allegra-transcatheter-heart-valve-5-20.webp?t=1779308345" type="image/jpeg" medium="image" fileSize="73313">
        <media:title type="plain">Biosensors International Allegra transcatheter heart valve</media:title>
        <media:description type="plain">Allegra transcatheter heart valve. Credit: Biosensors International </media:description>
      </media:content>
    </item>
    <item>
      <title>Genescience presents STAT6 degrader for atopic dermatitis</title>
      <description>
        <![CDATA[Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation. GenSciP166 was assayed in vitro as well as in vivo in the MC903 atopic dermatitis murine model.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731177</guid>
      <pubDate>Wed, 20 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731177-genescience-presents-stat6-degrader-for-atopic-dermatitis</link>
    </item>
    <item>
      <title>‘Detargeted’ targeted gene therapy improves activity in Pompe</title>
      <description>
        <![CDATA[A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme and the vector that delivers it to the target tissue while avoiding the liver. The findings suggest that combining an optimized transgene with a targeted capsid could significantly enhance the effectiveness of gene therapy for Pompe disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731174</guid>
      <pubDate>Wed, 20 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731174-detargeted-targeted-gene-therapy-improves-activity-in-pompe</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Acid-alpha-glucosidase-molecular-structure.webp?t=1779288468" type="image/jpeg" medium="image" fileSize="390572">
        <media:title type="plain">Acid alpha-glucosidase molecular structure isolated on black</media:title>
      </media:content>
    </item>
    <item>
      <title>Dual-payload ADC holds promise for treating HER2+ tumors </title>
      <description>
        <![CDATA[Antibody-drug conjugates (ADCs) with a dual payload, which deliver two distinct cytotoxic agents via a single antibody, are emerging therapeutics developed to address the limitations of classic ADCs. Primelink Biotherapeutics (Shenzhen) Co. Ltd. recently presented data for their dual-payload ADCs, highlighting PLB-015, which carries a TOP1 inhibitor and an ATR inhibitor with an anti-HER2 antibody and is designed to inhibit the DNA damage response activated by cancer cells when harmed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731163</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731163-dual-payload-adc-holds-promise-for-treating-her2-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/ADC-illustration.webp?t=1763043550" type="image/jpeg" medium="image" fileSize="320648">
        <media:title type="plain">Antibody-drug conjugates floating on light purple background</media:title>
      </media:content>
    </item>
    <item>
      <title>Biocryst’s BCX-17725 as new approach for Netherton syndrome</title>
      <description>
        <![CDATA[Netherton syndrome is a rare disease caused by loss of activity of the lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein, which in turn is caused by mutations in its encoding gene, SPINK5. This deficiency leads to the triggering of the kallikrein (KLK) signaling cascade resulting in skin barrier dysfunction, inflammation and atopy. At the recent Society for Investigative Dermatology meeting, Biocryst Pharmaceuticals Inc. presented early data on BCX-17725, a KLK5/KLK14 inhibitor fusion protein developed to restore LEKTI functioning in patients with Netherton syndrome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731160</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731160-biocrysts-bcx-17725-as-new-approach-for-netherton-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-anatomy-and-DNA.webp?t=1777580724" type="image/jpeg" medium="image" fileSize="187452">
        <media:title type="plain">Skin anatomy and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis </title>
      <description>
        <![CDATA[Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of atopic dermatitis (AD). Targeting STAT6, the key downstream mediator, offers a more selective strategy that could reproduce biologic efficacy while reducing off-target effects.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731157</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731157-recludixs-first-in-class-stat6-inhibitor-shows-efficacy-in-atopic-dermatitis</link>
    </item>
    <item>
      <title>KC-1101 has best-in-class potential for TACC3-expressing tumors</title>
      <description>
        <![CDATA[Transforming acidic coiled-coil-containing protein 3 (TACC3) is a core member of multiprotein complexes that regulate microtubule- and centrosome-related processes. Its aberrant expression is found in several cancer types with poor prognosis, thus highlighting it as a candidate therapeutic target. Researchers from Beijing Konruns Pharmaceutical Co. Ltd. have presented data for KC-1101, a TACC3 inhibitor for treating aggressive cancers with centrosome amplification.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731144</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731144-kc-1101-has-best-in-class-potential-for-tacc3-expressing-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-gene-therapy-T-cell.webp?t=1588880268" type="image/png" medium="image" fileSize="561911">
        <media:title type="plain">Cancer cell, dropper, test tubes</media:title>
      </media:content>
    </item>
    <item>
      <title>GPX-002 restores β-cell function in a diabetes model </title>
      <description>
        <![CDATA[Type 2 diabetes is marked by insulin resistance coupled with insufficient insulin secretion due to early β-cell dysfunction and progressive loss of β-cell mass. Pdx1 and MafA, critical for maintaining β-cell function, are progressively reduced under metabolic stress and in patients, driving disease progression. Researchers at the University of Pittsburgh have reported efficacy data demonstrating successful pancreatic delivery of GPX-002, an AAV-Pdx1/MafA construct, in HFD mice.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731140</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731140-gpx-002-restores-cell-function-in-a-diabetes-model</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-metabolic-pancreas-anatomy-illustration.webp?t=1774020868" type="image/jpeg" medium="image" fileSize="655771">
        <media:title type="plain">Pancreas anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>ZMS-4084 shows robust antitumor efficacy in MSI-H cancer models </title>
      <description>
        <![CDATA[Werner syndrome helicase (WRN), belonging to the RecQ helicase family, represents a synthetic lethal vulnerability in MSI-H cancers, providing a strong rationale for therapeutic inhibition. Researchers from Simcere Zaiming Pharmaceutical Co. Ltd. reported the discovery and preclinical characterization of ZMS-4084, a novel WRN inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731128</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731128-zms-4084-shows-robust-antitumor-efficacy-in-msi-h-cancer-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-under-magnifying-glass.webp?t=1611092780" type="image/png" medium="image" fileSize="453785">
        <media:title type="plain">Cancer cells under magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>NTX-819, a novel mGlu7 NAM for psychiatric disorders</title>
      <description>
        <![CDATA[Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on NTX-819, a potential first-in-class, potent and selective negative allosteric modulator (NAM) of mGlu7. NTX-819 was tested in vivo in rats using behavioral tests that are relevant to disorders such as obsessive-compulsive disorder (OCD), agitation and mania/psychosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731127</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731127-ntx-819-a-novel-mglu7-nam-for-psychiatric-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Psychiatry-illustration.webp?t=1710887261" type="image/jpeg" medium="image" fileSize="103707">
        <media:title type="plain">Two silhouettes with tangle, gear, spiral</media:title>
      </media:content>
    </item>
    <item>
      <title>Ensem’s ETX-929 is candidate for KRAS mutant tumors</title>
      <description>
        <![CDATA[Ensem Therapeutics Inc. has presented data for ETX-929, a small-molecule, oral pan-KRAS inhibitor with potent ON and OFF dual-state inhibitory activity for both wild-type and mutant KRAS.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731125</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731125-ensems-etx-929-is-candidate-for-kras-mutant-tumors</link>
    </item>
    <item>
      <title>ASGCT 2026: Directed evolution in gene therapy</title>
      <description>
        <![CDATA[Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and delivery vectors. Molecular diversification methods are increasingly sophisticated and are now accelerated by machine learning and AI tools, as showcased at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) held in Boston this week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731119</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731119-asgct-2026-directed-evolution-in-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-and-genome-editing.webp?t=1778858165" type="image/jpeg" medium="image" fileSize="96216">
        <media:title type="plain">DNA and genome editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Blueprint’s BLU-448, a CDK4 degrader for HR+/HER2- breast cancer</title>
      <description>
        <![CDATA[Work at Blueprint Medicines Corp. to identify a selective and potent CDK4 degrader led to the identification of BLU-448, with minimal activity against CDK6 for treating HR+/HER2- breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731102</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731102-blueprints-blu-448-a-cdk4-degrader-for-hr-her2-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-mammogram.webp?t=1617994360" type="image/png" medium="image" fileSize="409105">
        <media:title type="plain">Mammogram</media:title>
      </media:content>
    </item>
    <item>
      <title>Epirium’s 15-PGDH inhibitor IBD candidates improve disease outcomes in models</title>
      <description>
        <![CDATA[Epirium Bio Inc. has developed a series of small-molecule 15-PGDH inhibitors, the phase II-ready MF-300 and preclinical candidate MF-1305, as potential therapeutics for inflammatory bowel disease (IBD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731101</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731101-epiriums-15-pgdh-inhibitor-ibd-candidates-improve-disease-outcomes-in-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-microbiome.webp?t=1589217172" type="image/png" medium="image" fileSize="442923">
        <media:title type="plain">Intestine</media:title>
      </media:content>
    </item>
    <item>
      <title>QW-5-70 exhibits antitumor activity in multidrug-resistant tumors</title>
      <description>
        <![CDATA[Resistance to microtubule-targeting agents such as taxanes and vinca alkaloids is often driven by drug efflux and changes in tubulin behavior. Targeting the colchicine-binding site provides an alternative strategy that may circumvent these resistance mechanisms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731097</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731097-qw-5-70-exhibits-antitumor-activity-in-multidrug-resistant-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Precision-targeted-therapy-concept.webp?t=1754501515" type="image/jpeg" medium="image" fileSize="188108">
        <media:title type="plain">Precision targeted therapy concept illustrated by dart hitting bullseye of target</media:title>
      </media:content>
    </item>
    <item>
      <title>ASGCT 2026: Uncovering the mechanisms of AAV toxicity</title>
      <description>
        <![CDATA[Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other delivery strategies. Each combination is optimized for a specific cell type and indication, aiming to overcome challenges such as efficacy, specificity and toxicity. On May 13, 2026, two sessions included in the scientific symposia of the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), being held in Boston this week, addressed AAV-related toxicities, which have led to fatal cases in clinical trials and remain an area for improvement in approved therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731091</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731091-asgct-2026-uncovering-the-mechanisms-of-aav-toxicity</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Colorful-adeno-associated-viruses-AAVs.webp?t=1778776816" type="image/png" medium="image" fileSize="1832336">
        <media:title type="plain">3D illustration of adeno-associated viruses</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere’s SCR-A019 shows promise for mesothelin-expressing tumors</title>
      <description>
        <![CDATA[Mesothelin (MSLN) is a highly expressed protein in several cancer types but with limited expression in normal tissues. Simcere Pharmaceutical Co. Ltd. has presented preclinical data on the characterization of SCR-A019, an antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload and an antibody that binds to membrane Mesothelin (MSLN) over soluble MSLN and has shown robust antitumor efficacy in several cell-derived xenograft models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731079</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731079-simceres-scr-a019-shows-promise-for-mesothelin-expressing-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Targeted-cancer-cell.webp?t=1748961673" type="image/jpeg" medium="image" fileSize="966728">
        <media:title type="plain">Cancer cell in the cross-hairs</media:title>
      </media:content>
    </item>
    <item>
      <title>BTX-001 enables single-dose treatment for geographic atrophy</title>
      <description>
        <![CDATA[Researchers from Beacon Therapeutics Holdings Ltd. reported the development of BTX-001, an intravitreal gene therapy designed to target the complement pathway through delivery of a C5 inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731075</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731075-btx-001-enables-single-dose-treatment-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-DNA.webp?t=1621374169" type="image/png" medium="image" fileSize="619372">
        <media:title type="plain">Eye and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>HEC Pharma presents oral small-molecule PD-L1 inhibitor</title>
      <description>
        <![CDATA[HEC Pharma Co. Ltd. recently presented HEC-201625, a small-molecule PD-L1 inhibitor for cancer immunotherapy that blocks the PD-1/PD-L1 signaling pathway. HEC-201625 was tested in vitro and in vivo in MC38 syngeneic murine model, as well as in xenograft A375 and NCI-H358 models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731017</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731017-hec-pharma-presents-oral-small-molecule-pd-l1-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cells-receptors-inhibitors.webp?t=1667926694" type="image/png" medium="image" fileSize="1347625">
        <media:title type="plain">Concept art for cells receptors, inhibitors</media:title>
      </media:content>
    </item>
    <item>
      <title>OPGx-BEST1 restores BEST1 expression in retinal cells</title>
      <description>
        <![CDATA[Researchers at Opus Genetics Inc. reported the efficacy of OPGx-BEST1, an AVV-based gene therapy developed to deliver a functional BEST1 transgene to retinal pigment epithelium (RPE) cells to re-establish normal BEST1 expression and activity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731014</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731014-opgx-best1-restores-best1-expression-in-retinal-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Test-tube-dropper-research.webp?t=1588878251" type="image/png" medium="image" fileSize="320857">
        <media:title type="plain">Test tube, dropper, DNA illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>JUV-161 reverses structural and functional muscle decline</title>
      <description>
        <![CDATA[At the European Congress of Endocrinology in Prague, researchers from Juvena Therapeutics Inc. presented the effects of JUV-161, a fusion protein consisting of human insulin-like growth factor 2 linked to human serum albumin, in preclinical models of myotonic dystrophy type 1 (DM1) and sarcopenia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731013</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731013-juv-161-reverses-structural-and-functional-muscle-decline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Muscle-tissue-fiber-detail.webp?t=1709912593" type="image/jpeg" medium="image" fileSize="173605">
        <media:title type="plain">Illustration of muscle anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>Soley Therapeutics reports data on new CKAP2 modulator STX-6398</title>
      <description>
        <![CDATA[Cytoskeleton-associated protein 2 (CKAP2) is the most potent microtubule growth factor identified so far and is considered an undruggable protein, often associated with malignant progression in cancer by targeting the FAK-ERK2 signaling pathway. Using its proprietary platform, Soley Therapeutics Inc. has discovered a small molecule that modulates CKAP2 – STX-6398.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730999</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730999-soley-therapeutics-reports-data-on-new-ckap2-modulator-stx-6398</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Doctor-chemistry-molecule-science-research.webp?t=1778511298" type="image/jpeg" medium="image" fileSize="481427">
        <media:title type="plain">Doctor hand touching virtual molecular structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Singlomics’ DXP-106 shows robust results in preclinical setting</title>
      <description>
        <![CDATA[The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730998</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730998-singlomics-dxp-106-shows-robust-results-in-preclinical-setting</link>
    </item>
    <item>
      <title>First long-acting, intra-articular multikinase inhibitor for OA</title>
      <description>
        <![CDATA[Researchers from Rottapharm Biotech Srl have reported preclinical efficacy data on CR-10049, a long-acting osteoarthritis-targeted multikinase inhibitor, designed to treat both osteoarthritis pain and inflammatory joint degeneration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730997</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730997-first-long-acting-intra-articular-multikinase-inhibitor-for-oa</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Hand-wrist-inflammation-arthritis-joint-pain.webp?t=1771431082" type="image/jpeg" medium="image" fileSize="393611">
        <media:title type="plain">X-ray image of hand and wrist</media:title>
      </media:content>
    </item>
    <item>
      <title>Takeda’s anti-CCR8 ADC shows potent antitumor activity</title>
      <description>
        <![CDATA[Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730954</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730954-takedas-anti-ccr8-adc-shows-potent-antitumor-activity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/TME-tumor-microenvironment-3D.webp?t=1699370810" type="image/jpeg" medium="image" fileSize="457538">
        <media:title type="plain">3D Rendering of tumor microenvironment</media:title>
      </media:content>
    </item>
    <item>
      <title>BD-200 is strong dual-targeting ADC candidate for cancer</title>
      <description>
        <![CDATA[Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730953</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730953-bd-200-is-strong-dual-targeting-adc-candidate-for-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Immune-antibody-drug-capsule.webp?t=1778251154" type="image/png" medium="image" fileSize="660418">
        <media:title type="plain">3D rendering of a drug capsule and flying antibodies</media:title>
      </media:content>
    </item>
  </channel>
</rss>
